HOME
Leading the way to a cure

LUPUS NEWS

Research results from Catholic University of Korea, Department of Internal Medicine update knowledge of systemic lupus erythematosus risk factors

April 6, 2010

Scientists discuss in 'Incidence of cancer among female patients with systemic lupus erythematosus in Korea' new findings in systemic lupus erythematosus. According to a study from Seoul, South Korea, "This study aims to ascertain the incidence of cancer in patients with systemic lupus erythematosus (SLE) in comparison with that in the general population in Korea, and to identify the cancer-types, the organ involvement, and the association with immunosuppressive therapy. The study subjects were consecutive SLE patients evaluated at Kangnam St."

"Mary's hospital between 1997 and 2007. The incidence rate of cancer was calculated and was analyzed in comparison to that of age-and sex-matched cohort obtained from the Korea National Cancer Registry. Nine hundred fourteen patients were observed for a total of 5,716 person-years. A total of 16 cases of cancer occurred. The average age at the diagnosis of cancer and the mean disease duration were 43 years and 11 years, respectively. The standardized incidence ratio (SIR) of all cancers was 1.45 (95% CI 0.74-2.16); The SIRs for the three most frequent cancers were 3.42 for cervix cancer (CI 0.00-7.26), 15.37 for non-Hodgkin's lymphoma (NHL; CI 2.90-37.68), and 43.55 for bladder cancer (CI 8.21-106.78). There were significant differences in the hematologic and renal involvement between SLE patients with cancer and without. Cyclophosphamide therapy, especially with cumulative dose more than 6 g (p=0.017), seemed to contribute to the increased risk of cancer. Long disease duration, damage, and hematologic involvement were associated with increased risk of cancer occurrence. SLE patients are at high risk for NHL and bladder cancer," wrote K.Y. Kang and colleagues, Catholic University of Korea, Department of Internal Medicine (see also Systemic Lupus Erythematosus Risk Factors).

Read the full article here

Source pharmacychoice.com


Research results from Catholic University of Korea, Department of Internal Medicine update knowledge of systemic lupus erythematosus risk factors

April 6, 2010

Scientists discuss in 'Incidence of cancer among female patients with systemic lupus erythematosus in Korea' new findings in systemic lupus erythematosus. According to a study from Seoul, South Korea, "This study aims to ascertain the incidence of cancer in patients with systemic lupus erythematosus (SLE) in comparison with that in the general population in Korea, and to identify the cancer-types, the organ involvement, and the association with immunosuppressive therapy. The study subjects were consecutive SLE patients evaluated at Kangnam St."

"Mary's hospital between 1997 and 2007. The incidence rate of cancer was calculated and was analyzed in comparison to that of age-and sex-matched cohort obtained from the Korea National Cancer Registry. Nine hundred fourteen patients were observed for a total of 5,716 person-years. A total of 16 cases of cancer occurred. The average age at the diagnosis of cancer and the mean disease duration were 43 years and 11 years, respectively. The standardized incidence ratio (SIR) of all cancers was 1.45 (95% CI 0.74-2.16); The SIRs for the three most frequent cancers were 3.42 for cervix cancer (CI 0.00-7.26), 15.37 for non-Hodgkin's lymphoma (NHL; CI 2.90-37.68), and 43.55 for bladder cancer (CI 8.21-106.78). There were significant differences in the hematologic and renal involvement between SLE patients with cancer and without. Cyclophosphamide therapy, especially with cumulative dose more than 6 g (p=0.017), seemed to contribute to the increased risk of cancer. Long disease duration, damage, and hematologic involvement were associated with increased risk of cancer occurrence. SLE patients are at high risk for NHL and bladder cancer," wrote K.Y. Kang and colleagues, Catholic University of Korea, Department of Internal Medicine (see also Systemic Lupus Erythematosus Risk Factors).

Read the full article here

Source pharmacychoice.com



1.5 million

people in the U.S. have Lupus.

100 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software